GNMLF Stock Genomma Lab International SAB DE CV (GNMLF, $0.93) was a top loser this quarter, falling -16.54%

GET DAILY SIGNALS

Get AI intraday signals

GNMLF - Genomma Lab International SAB DE CV

Loading...

Price: $0.9348

Daily change: -$0.0264 (-2.75%)

Daily volume: 100

3-month price change: -$0.1852 (-16.54%)

Capitalization: $908.7M

Industry: Pharmaceuticals: Generic

GNMLF's RSI Indicator sits in oversold zone for 5 days

The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.

Technical Analysis (Indicators)

Bullish Trend Analysis

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on October 10, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on GNMLF as a result. In of 38 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

GNMLF moved below its 50-day moving average on October 10, 2025 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for GNMLF crossed bearishly below the 50-day moving average on October 10, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.498) is normal, around the industry mean (17.766). P/E Ratio (9.120) is within average values for comparable stocks, (72.923). Projected Growth (PEG Ratio) (0.463) is also within normal values, averaging (2.078). Dividend Yield (0.044) settles around the average of (0.030) among similar stocks. P/S Ratio (0.893) is also within normal values, averaging (46.182).

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. GNMLF’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GNMLF’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 91, placing this stock worse than average.